

The Medical Letter[®]

on Drugs and Therapeutics

Volume 65

Published online January 13, 2023

Online
Article

IN THIS ISSUE

COVID-19 Update: *Evusheld* Unlikely to Neutralize XBB.1.5 Omicron Variant

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying, or any distribution of this material without permission to a nonsubscriber is prohibited.

Sharing a password with a nonsubscriber or otherwise making the contents of this site available to third parties is prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769

The Medical Letter®

on Drugs and Therapeutics

Volume 65

Published online January 13, 2023

Online
Article

IN THIS ISSUE

COVID-19 Update: *Evusheld* Unlikely to Neutralize XBB.1.5 Omicron Variant

COVID-19 UPDATE

Evusheld Unlikely to Neutralize XBB.1.5 Omicron Variant

The FDA has warned that the investigational long-acting monoclonal antibodies tixagevimab and cilgavimab (*Evusheld* – AstraZeneca) are unlikely to neutralize the XBB.1.5 Omicron variant of SARS-CoV-2.¹ *Evusheld* is available under an Emergency Use Authorization (EUA) for IM pre-exposure prophylaxis of COVID-19 in persons ≥ 12 years old who weigh ≥ 40 kg and have either a history of a severe adverse reaction that prevents their vaccination against COVID-19 or moderate or severe immune compromise.^{2,3}

According to the FDA, because tixagevimab and cilgavimab do not neutralize the XBB Omicron variant of SARS-CoV-2, they are unlikely to neutralize the closely related XBB.1.5 variant.¹ The CDC has

estimated that the XBB.1.5 variant caused 43% of COVID-19 cases in the week ending January 14, 2023, up from 7% of cases 4 weeks earlier.⁴ ■

1. FDA. Drug safety and availability. FDA releases important information about risk of COVID-19 due to certain variants not neutralized by *Evusheld*. January 6, 2023. Available at: <https://bit.ly/3W4IYBZ>. Accessed January 13, 2023.
2. Tixagevimab and cilgavimab (*Evusheld*) for pre-exposure prophylaxis of COVID-19. *Med Lett Drugs Ther* 2022; 64:1.
3. COVID-19 update: Dosing interval for tixagevimab/cilgavimab (*Evusheld*). *Med Lett Drugs Ther* 2022; 64:e122.
4. CDC. COVID data tracker. Variant proportions. January 14, 2023. Available at: <https://bit.ly/3Ka3HhH>. Accessed January 13, 2023.

Additional Content Available Online: COVID-19 Tables/Charts

Please check our website for the latest information on COVID-19, including our continuously updated tables/charts on treatments, vaccines, and dosing recommendations. Available at: www.medicalletter.org/drugs-for-covid-19.

PRESIDENT: Mark Abramowicz, M.D.; **VICE PRESIDENT, EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhM, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli

EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer. The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:

The Medical Letter, Inc.
145 Huguenot St. Ste. 312
New Rochelle, NY 10801-7537
www.medicalletter.org

Customer Service:

Call: 800-211-2769 or 914-235-0500
Fax: 914-632-1733
E-mail: custserv@medicalletter.org

Permissions:

To reproduce any portion of this issue,
please e-mail your request to:
permissions@medicalletter.org

Subscriptions (US):

1 year - \$159; 2 years - \$298;
3 years - \$398. \$65 per year
for students, interns, residents,
and fellows in the US and Canada.
Reprints - \$45 per issue or article

Site License Inquiries:

E-mail: SubQuote@medicalletter.org
Call: 800-211-2769
Special rates available for bulk
subscriptions.

Get Connected:    

Copyright 2023. ISSN 1523-2859

